Abstract
The treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) remains challenging. Radiation therapy (RT) combined with chemotherapy is more effective than RT alone, and concomitant chemoradiation has yielded improved survival compared to sequential chemotherapy and RT, but at the cost of heightened toxicity, especially esophagitis. The majority of randomized chemoradiation trials have featured cisplatin or carboplatin based chemotherapy, usually in combination with either etoposide or paclitaxel, with median survival times of 16–18 months, and 5 year survival rates of 15 to 20% at best. In this chapter, we describe recent studies employing pemetrexed and nab-paclitaxel, each of which has been extensively investigated in advanced disease, the former yielding improved progression-free and overall survival in adenocarcinoma both in the frontline and maintenance setting, the latter yielding superior response rates in squamous cell carcinoma compared to conventional paclitaxel in chemo-naïve patients. Both agents have demonstrated safety and efficacy in LA-NSCLC in conjunction with RT. Whether these agents will ever prove superior to either etoposide or paclitaxel in this setting will require careful, phase III testing.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
ABI 007. Drugs RD (2004) 5:155–159 (For more details seedoi: 10.1200/JCO.2005.03.7135
Aupérin A, Rolland E, Curran WJ et al (2007) Concomitant radio-chemotherapy (RT-CT) versus sequential RT–CT in locally advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs): A1-04. J Thorac Oncol 2:S310
Brade A, Bezjak A, MacRae R (2011) Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small cell lung cancer. Int J Radiat Oncol Biol Phys 79(5):1395–1401 [Epub 2010 Jun 3]
Choy H, Curran WJ, Scott CB , Bonomi P, Travis P, Haluschak J, Belani CP (2002) Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 21
Choy H, Schwartzberg LS, Dakhil SR (2010) Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update. J Clin Oncol 28:15s [suppl; abstr 7082]
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440 [Epub 2009 Sep 18. PMID: 19767093]
Curran W, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Russell A, Byhardt R, Machtay M, Sause W, Cox JD (2010) Phase III Comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III non-small cell lung cancer (NSCLC): report of radiation therapy oncology group (RTOG) 9410. JNCI (in press)
Damascelli B, Cantu G, Mattavelli F et al (2001) Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92:2592–2602
Desai N, Trieu V, Yao Z et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albuminbound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324
Furuse K et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17(9):2692–2699
Green MR, Manikhas GM, Orlov S et al (2006) Abraxane(R), a novel Cremophor(R)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small cell lung cancer. Ann Oncol 17:126–138
Govindan R, Bogart J, Wang X et al (2009) Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. Program and abstracts of the 45th annual meeting of the American Society of Clinical Oncology, May 29–June 2, Orlando, Florida, Abstract 7505
Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compare with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597
Hariri G, Yan H, Wang H, Han Z, Hallahan DE (2010) Radiation-guided drug delivery to mouse models of lung cancer. Clin Cancer Res 16(20):4968–4977 [Epub 2010 Aug 27]
Ibrahim NK, Desai N, Legha S et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044
Ibrahim NK, Samuels B, Page R et al (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel in women with metastatic breast cancer. J Clin Oncol 23:6019–6026
Movsas B, Scott C, Langer C et al (2005) Randomized trial of amifostine in locally advanced non-small cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23(10):2145–2154
Nyman DW, Campbell KJ, Hersh E et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785–7793
Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26:3543–3551
Seiwert TY, Connell PP, Mauer AM et al (2007) A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 13:515–522
Socinski MA, Bondarenko IN, Karaseva NA (2010) Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 28:18s [suppl; abstr LBA7511]
Sparreboom A, Baker SD, Verweij J (2005) Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? J Clin Oncol 23:7765–7767
Wiedenmann N, Valdecanas D, Hunter N et al (2007) Radiocurability and therapeutic gain 130-nm albumin-bound paclitaxel enhances tumor. Clin Cancer Res 13:1868–1874
Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M (2010) Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28(23):3739–3745 Epub 2010 Jul 12
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Langer, C.J. (2011). Novel Cytotoxic Agents in Combination with Radiation in the Management of Locally Advanced Non-Small Cell Lung Cancer: Focus on Pemetrexed and Nab-Paclitaxel [Abraxane]. In: Jeremic, B. (eds) Advances in Radiation Oncology in Lung Cancer. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2011_314
Download citation
DOI: https://doi.org/10.1007/174_2011_314
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-19924-0
Online ISBN: 978-3-642-19925-7
eBook Packages: MedicineMedicine (R0)